Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN

Conditions:   Head and Neck Squamous Cell Carcinoma;   HPV Positive Oropharyngeal Squamous Cell Carcinoma;   HPV-Related Carcinoma
Interventions:   Biological: TG4001;   Drug: Avelumab
Sponsors:   Transgene;   Merck KGaA;   EMD Serono Research & Development Institute, Inc.;   Pfizer
Not yet recruiting - verified August 2017

http://ift.tt/2xvMfyp